Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 9 , ISSUE 1 ( January-March, 2017 ) > List of Articles

REVIEW ARTICLE

Prediction of Preeclampsia: Role of Antiangiogenic and Proangiogenic Biomarkers

Ruchika Garg

Citation Information : Garg R. Prediction of Preeclampsia: Role of Antiangiogenic and Proangiogenic Biomarkers. J South Asian Feder Obs Gynae 2017; 9 (1):47-52.

DOI: 10.5005/jp-journals-10006-1456

Published Online: 01-08-2012

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract
PDF Share
  1. Preeclampsia. Lancet 2010 Aug;376(9741):631-644.
  2. Maternal mortality from preeclampsia/ eclampsia. Semin Perinatol 2012 Feb;36(1):56-59.
  3. Pre-eclampsia and the hypertensive disorders of pregnancy. Br Med Bull 2003;67:161-176.
  4. Am J Obstet Gynecol 2000 Jul;183(1):S1-S22.
  5. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003 Mar;111(5):649-658.
  6. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999 Feb;180(2 Pt 1):499-506.
  7. Pre-eclampsia treatment according to scientific evidence. Rev Bras Ginecol Obstet 2010 Sep;32(9):459-468.
  8. Determinants of maternal mortality in eclampsia in India. Aust N Z J Obstet Gynaecol 1994;34:537-539.
  9. Role of vitamins C and E in regulating antioxidant and pro-oxidant markers in preeclampsia. J Clin Biochem Nutr 2008 Nov;43(3):210-20.
  10. Preeclampsia: new insights. Curr Opin Nephrol Hypertens 2007 May;16(3):213-220.
  11. Experimental preeclampsia produced by chronic constriction of the lower aorta: validation with longitudinal blood pressure measurements in conscious rhesus monkeys. Am J Obstet Gynecol 1993 Jul;169(1):215-223.
  12. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001 Oct;185(4):792-797.
  13. Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol 2000 Jan;156(1):321-331.
  14. Current topic: the uteroplacental renin–angiotensin system. Placenta 2000 Jul-Aug;21(5-6):468-477.
  15. Molecular mechanisms of preeclampsia. Microvasc Res 2008 Jan;75(1):1-8.
  16. Placental stress and pre-eclampsia: a revised view. Placenta 2009 Mar;30(Suppl A):S38-S42.
  17. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997 May;99(9):2139-2151.
  18. Angiogenic factors and preeclampsia. Semin Nephrol 2011 Jan;31(1):33-46.
  19. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997 May;99(9):2152-2164.
  20. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 2007 Aug;197(2):176.e1-171.e6.
  21. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004 Dec;104(6):1367-1391.
  22. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011 Jun;123(24):2856-2869.
  23. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003 Nov;88(11):5555-5563.
  24. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006 Jun;12(6):642-649.
  25. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992 Sep;267(27):19027-19030.
  26. Human first-trimester decidua vascular density: an immunohistochemical study using VE-cadherin and endoglin as endothelial cell markers. Am J Reprod Immunol 2000 Jul;44(1):9-15.
  27. Expression of normal and truncated forms of human endoglin. Biochem J 1999 May;339(Pt 3):579-588.
  28. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 1991 Nov;67(4):785-795.
  29. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006 Sep;355(10):992-1005.
  30. Soluble endoglin as a secondtrimester marker for preeclampsia. Am J Obstet Gynecol 2007 Aug;197(2):174.e1-174.e5.
  31. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004 Feb;350(7):672-683.
  32. Preeclampsia and the antiangiogenic state. Pregnancy Hypertens 2011 Jan;1(1):17-21.
  33. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008 Jan;21(1):9-23.
  34. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010 Aug;151(2):122-129.
  35. Decreased proportion of peripheral blood vascular endothelial growth factor-expressing T and natural killer cells in preeclampsia. Am J Obstet Gynecol 2010 Dec;203(6):567.e1-567.e8.
  36. Potential markers of preeclampsia – a review. Reprod Biol Endocrinol 2009 Jul;7:70-84.
  37. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005 Nov;46(5):1077-1085.
  38. New markers in preeclampsia. Clin Chim Acta 2010 Nov;411(21-22):1591-1595.
  39. Signal transduction and biological function of placenta growth factor in primary human trophoblast. Biol Reprod 1999 Apr;60(4):887-892.
  40. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010 Sep;33(9):892-898.
  41. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009;24:147-158.
  42. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as firsttrimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008 Sep;199(3):266.e1-266.e6.
  43. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 2009 Aug;29(8):753-760.
  44. Low levels of maternal serum PAPP-A in the first trimester and the risk of preeclampsia. Prenat Diagn 2008 Jan;28(1):7-10.
  45. First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia. Prenat Diagn 2009 Nov;29(11):1066-1068.
  46. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med 2011 Apr;31(2):72-80.
  47. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets 2011 Aug;10(4):272-282.
  48. NGAL: a marker molecule for the distressed kidney? Clin Lab Int 2005 Nov;29:39-41.
  49. Neutrophil gelatinaseassociated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005 Apr;365(9466):1231-1238.
  50. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand 2008;87(12):1370-1373.
  51. Early screening for preeclampsia. Rev Bras Ginecol Obstet 2011 Nov;33(11):367-375.
  52. Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17). Oncodev Biol Med 1983;4(5):343-350.
  53. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006 Jan;27(1):13-17.
  54. Neutrophil gelatinaseassociated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 2010;89(2):275-278.
  55. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 2008 Jul;18(5):186-194.
  56. First trimester serum markers to predict preeclampsia. Wien Med Wochenschr 2012 May;162(9-10):191-195.
  57. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992 Nov;267(31):22190-22197.
  58. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol Scand 2009;88(7): 846-849.
  59. Cell-cell contact mechanisms. Curr Opin Immunol 1992 Feb;4(1):33-37.
  60. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004 Dec;104(6):1367-1391.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.